白介素-1受体阻滞剂利洛纳塞的研究进展

Progress in the research of the interleukin-1 blocker rilonacept

冷吡啉相关周期性综合征(CAPS)是一种遗传性炎症型疾病,包括家族性寒冷型自身炎症性综合征(FCAS)和穆-韦二氏综合征(MWS)。该疾病的症状包括发热、寒战、皮疹、疲劳、关节痛和眼睛发红。促炎症反应细胞因子白介素-1(IL-1)为该病的致病因子,因此调节IL-1的活性成为缓解CAPS症状的重要治疗方法。利洛纳塞(IL-1受体阻滞剂)已通过美国FDA批准,用于治疗此罕见的炎症性疾病。利洛纳塞与IL-1b和IL-1a有高度的亲和性,与之结合并抑制IL-1的活性。文中对该药物作用机制、药动学、临床研究进展进行综述。

Cryopyrin-associated periodic syndromes （CAPS） is a spectrum of rare inherited inflammatory diseases, including familial cold autoinflammatory syndrome （FCAS） and Muckle-Wells syndrome （MWS）. Symptoms of the disorders include inflammatory reations such as fever, chills, rash, fatigue, joint pain, and eye redness. The proinflammatory cytokine interleukin-1 （IL-1） has been implicated as a pathogenic factor in the disease. Thus, neutralization of IL-1 activity has emerged as an important therapeutic strategy to alleviate the symptoms of CAPS. The U. S. Food and Drug Administration has approved rilonacept, an interleukin-1 blocker, to treat the rare inflammatory diseases. Rilonacept can blind to IL-1b and IL-1a with high affinity and potently inhibit IL-1 activity. This article briefly reviewed the recent progress in clinical application of rilonacept.